Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - Phio Pharmaceuticals Corp. | Financial_Report.xls |
EX-5.1 - EX-5.1 - Phio Pharmaceuticals Corp. | d902036dex51.htm |
EX-4.3 - EX-4.3 - Phio Pharmaceuticals Corp. | d902036dex43.htm |
EX-4.4 - EX-4.4 - Phio Pharmaceuticals Corp. | d902036dex44.htm |
EX-10.17 - EX-10.17 - Phio Pharmaceuticals Corp. | d902036dex1017.htm |
EX-10.19 - EX-10.19 - Phio Pharmaceuticals Corp. | d902036dex1019.htm |
EX-10.18 - EX-10.18 - Phio Pharmaceuticals Corp. | d902036dex1018.htm |
EX-10.16 - EX-10.16 - Phio Pharmaceuticals Corp. | d902036dex1016.htm |
S-1/A - FORM S-1/A - Phio Pharmaceuticals Corp. | d902036ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
RXi Pharmaceuticals Corporation
Marlborough, Massachusetts
We hereby consent to the use in the Prospectus constituting a part of this Amendment No. 1 to Registration Statement on Form S-1 of our report dated March 30, 2015, relating to the financial statements of RXi Pharmaceuticals Corporation, which is contained in that Prospectus.
We also consent to the reference to us under the caption Experts in the Prospectus.
/s/ BDO USA, LLP |
Boston, MA |
May 19, 2015 |